ClinicalTrials.gg
RecruitingNCT06008119Updated Sep 9, 2026

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

A Phase 3 interventional study of Tunlametinib plus Vemurafenib and Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab in Colorectal Cancer Metastatic, sponsored by Shanghai Kechow Pharma, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Shanghai Kechow Pharma, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
283rd of 894
165 · median 80
Started
2023
with 140 others
Phase 3
124 of 1,139
45 open now
Primary completion
2026-12
later than 301 of 605 live
Registered
639th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 283rd largest by planned enrollment of the 894 interventional ones that give a count, is one of 141 that started in 2023, is one of 124 in phase 3, reaches primary completion later than 301 of the 605 other live ones, and was the 639th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, Phase 3 study

Read the detailed description

This is a multicenter, randomized, open-label, Phase 3 study to evaluate Tunlamatinib plus Vemurafenib versus Investigator's choice of Chemotherapy based treatment as controls in patients with BRAFV600E mutant Metastatic Colorectal Cancer (CRC) whose disease has progressed after 1 or more prior regimens in the metastatic setting.

03

Conditions studied

  • Colorectal Cancer Metastatic

Keywords

  • BRAFV600E mutant
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:

    1. Before study entry, written must be obtained from the patient prior to performing any study-related procedures.
    2. Male or female patients with 18 to 70 years of age at time of informed consent;
    3. Histological or confirmed CRC
    4. Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory (BRAFV600 is permitted)
    5. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly obtained) for confirmatory central laboratory testing of BRAF mutation status.
    6. Progression of disease after 1 or more prior regimens in the metastatic setting
    7. At least 1 site of radiographically by 1.1
    8. (ECOG) Performance Status(PS) of 0 to 1;
    9. ≥ 3 months;
    10. Can swallow the medicine,
    11. Adequate hematologic, renal, cardiac and liver function as defined by laboratory values performed within 7 days prior to initiation of dosing:
    12. Be willing and able to complete all the study procedures and follow-up examinations.

Exclusion Criteria:

  • Exclusion Criteria:

    1. Prior treatment with any BRAF and MEK inhibitor;
    2. Known to receive the treatment of control arm (according to latest PI).
    3. Symptomatic or
    4. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or medications or surgery) ≤12 months prior to randomization
    5. Known history of acute or chronic pancreatitis
    6. Uncontrolled GI bleeding, Dysphagia, nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption.
    7. Serious cardiovascular disease , including uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia , deep vein thrombosis or pulmonary emboli or cerebrovascular events ≤ 6 months prior to starting study treatment;
    8. History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
    9. Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
    10. Uncontrolled blood pressure despite medical treatment
    11. Concurrent or previous other within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
    12. Residual (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy
    13. Anti-(+) , Anti-TP( +); Active or infection …….
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Experimental

    Tunlamatinib plus Vemurafenib

    Drug: Tunlametinib plus Vemurafenib

  • Active comparator
    Control

    Investigators' choice

    Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    defined as the time from first dose to the earliest documented disease progression or death due to any cause

    Time frame: up to 12 months

Secondary outcomes

  1. Overall Survival(OS)

    defined as the time from the date of taking drugs to the date of death due to any cause. After disease progression, participants in the control group can crossover to receive the experimental drug treatment if they meet the crossover enrollment criteria. The median survival time of the two groups will be estimated by Kaplan-Meier method, and the hazard ratio (HR) between the two groups will be estimated use the Cox proportional hazards model in FAS, and OS will be adjusted using the following two methods: 1. Rank Preserving Structural Failure Time Model (RPSFTM): Corrects survival outcomes for treatment crossover from the control group to the experimental group by estimating counterfactual survival times to infer the treatment effect without crossover. 2. Inverse Probability of Censoring Weighting (IPCW): Adjusts for informative censoring bias caused by treatment crossover. The weights will be derived from time-dependent censoring models.

    Time frame: up to 12 months

  2. Overall Response Rate(ORR)

    Defined as the proportion of subjects with an optimal response of CR or PR over the course of the study from enrollment to disease progression

    Time frame: up to 12 months

  3. Duration of Response(DOR)

    Defined as the time from the first CR or PR evaluation of tumor efficacy to the first occurrence of PD or death from any cause (whichever occurs first)

    Time frame: up to 12 months

  4. Disease control rate (DCR)

    roportion of subjects with response defined as CR, PR, and SD throughout the study from subjects first dose to disease progression or death

    Time frame: up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 37 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 23, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Dec 24, 2026
CompletionEst.
Dec 24, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06008119
Lead sponsor
Shanghai Kechow Pharma, Inc.
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Oct 25, 2023
Primary completion
Dec 24, 2026 (estimated)
Completion
Dec 24, 2026 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tunlametinib · Vemurafenib

Start the discussion